Marcus Williams, MD
Cardiovascular Disease · Fair Lawn, NJNPI 1467526525
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,634 of the $17,802 with a category attached, or 76.6%. Amgen accounts for 79.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $7,827 and has fallen 99.6% since, to $33 in 2025.
Across 109 payments — averaging $163.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Novartis$1K
- Boehringer Ingelheim$1K
- Johnson & Johnson$263
- Cvrx, Inc.$149
- Medtronic$148
- plus $759 from 15 others
Across 46 payments — averaging $5547.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$213K
- Bayer$35K
- Boehringer Ingelheim$4K
- Organon$3K
What the payments were for
- Consulting fees$2,24013%
- Speaking & faculty fees$13,63477%
- Food & beverage$1,89511%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 34 | $14,158 |
| Novartis | 4 | $1,250 |
| Boehringer Ingelheim | 5 | $1,075 |
| Johnson & Johnson | 20 | $263 |
| Cvrx, Inc. | 1 | $149 |
| Medtronic | 1 | $148 |
| AstraZeneca | 1 | $120 |
| Pfizer | 7 | $100 |
| Amarin Pharma, Inc. | 6 | $79 |
| Arbor Pharmaceuticals, Inc. | 6 | $75 |
| Merck | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Boston Scientific | 2 | $55 |
| Medline Industries LP | 2 | $48 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Scpharmaceuticals Inc. | 1 | $22 |
| G Medical Diagnostic Services, Inc. | 3 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$13,755
- PRADAXA$1,040
- Barostim Neo System$149
- COREVALVE EVOLUT R$148
- LOKELMA$120
How this compares
$17,802 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 403 | $438,451 |
| EntrestoSacubitril/Valsartan | 141 | $189,155 |
| XareltoRivaroxaban | 75 | $92,927 |
| Repatha SureclickEvolocumab | 59 | $75,378 |
| BrilintaTicagrelor | 20 | $18,002 |
| Metoprolol Succinate | 537 | $8,870 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 33 | $8,345 |
| Rosuvastatin Calcium | 390 | $5,936 |
| Nebivolol Hcl | 88 | $5,283 |
| Ranolazine ErRanolazine | 22 | $4,574 |
| Amlodipine Besylate | 390 | $3,615 |
| Atorvastatin Calcium | 263 | $3,410 |
| Chlorthalidone | 164 | $3,198 |
| Valsartan | 41 | $2,316 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 16 | $2,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $100 | $438,451403 claims |
| NovartisEntresto | $1,250 | $189,155141 claims |
| Johnson & JohnsonXarelto | $263 | $92,92775 claims |
| AstraZenecaBrilinta | $120 | $18,00220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Fair Lawn
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.